Clinical Trial Update: A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase 2 trial update for ICP-022 in recurrent or refractory Waldenstrom macroglobulinemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• ICP-022

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory | Phase 2 | Status: COMPLETED